[EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET MÉTHODES
申请人:TEMPERO PHARMACEUTICALS INC
公开号:WO2013019682A1
公开(公告)日:2013-02-07
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.
本发明涉及新型视黄醛酸相关孤儿受体γ(RORγ)调节剂及其在治疗由RORγ介导的疾病中的应用。
COMPOUNDS AND METHODS
申请人:Baloglu Erkan
公开号:US20140155381A1
公开(公告)日:2014-06-05
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.
本发明涉及新型視黃醇相關孤兒核受體γ(RORγ)調節劑及其在治療由RORγ介導的疾病中的使用。
TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION
申请人:Napoletano Mauro
公开号:US20130079339A1
公开(公告)日:2013-03-28
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.
[EN] "TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"<br/>[FR] ANTAGONISTES DU RÉCEPTEUR VANILLOÏDE TRPV1 AYANT UNE PARTIE BICYCLIQUE
申请人:PHARMESTE SRL
公开号:WO2011120604A1
公开(公告)日:2011-10-06
The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.
TRPV1 vanilloid receptor antagonists with a bicyclic portion
申请人:Napoletano Mauro
公开号:US09216975B2
公开(公告)日:2015-12-22
The invention discloses compounds of formula I
wherein Y is a group of formula A, B, C, D, or E:
and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description.
The compounds of formula I are TRPV1 antagonists and are useful as active ingredients of pharmaceutical compositions for the treatment of pain and other conditions ameliorated by the inhibition of the vanilloid receptor TRPV1.